BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 34435168)

  • 1. A Systematic Review of Systemic Treatment Options for Advanced Non-Clear Cell Renal Cell Carcinoma.
    Osterman CK; Rose TL
    Kidney Cancer; 2020; 4(1):15-27. PubMed ID: 34435168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
    Fernández-Pello S; Hofmann F; Tahbaz R; Marconi L; Lam TB; Albiges L; Bensalah K; Canfield SE; Dabestani S; Giles RH; Hora M; Kuczyk MA; Merseburger AS; Powles T; Staehler M; Volpe A; Ljungberg B; Bex A
    Eur Urol; 2017 Mar; 71(3):426-436. PubMed ID: 27939075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy.
    Graham J; Wells JC; Dudani S; Gan CL; Donskov F; Lee JL; Kollmannsberger CK; Meza L; Beuselinck B; Hansen A; North SA; Bjarnason GA; Sayegh N; Kanesvaran R; Wood LA; Hotte SJ; McKay RR; Choueiri TK; Heng DYC
    Eur J Cancer; 2022 Aug; 171():124-132. PubMed ID: 35717820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma.
    Tannir NM; Plimack E; Ng C; Tamboli P; Bekele NB; Xiao L; Smith L; Lim Z; Pagliaro L; Araujo J; Aparicio A; Matin S; Wood CG; Jonasch E
    Eur Urol; 2012 Dec; 62(6):1013-9. PubMed ID: 22771265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic Treatment for Advanced and Metastatic Non-Clear Cell Renal Cell Carcinoma: Examining Modern Therapeutic Strategies for a Notoriously Challenging Malignancy.
    Drobner J; Portal D; Runcie K; Yang Y; Singer EA
    J Kidney Cancer VHL; 2023; 10(3):37-60. PubMed ID: 37789902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies.
    Ciccarese C; Iacovelli R; Brunelli M; Massari F; Bimbatti D; Fantinel E; De Marco V; Porcaro AB; Martignoni G; Artibani W; Tortora G
    Eur J Cancer; 2017 Sep; 83():237-246. PubMed ID: 28756136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis.
    Chahoud J; Msaouel P; Campbell MT; Bathala T; Xiao L; Gao J; Zurita AJ; Shah AY; Jonasch E; Sharma P; Tannir NM
    Oncologist; 2020 Mar; 25(3):252-258. PubMed ID: 32162795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in non-clear cell renal cell carcinoma management: From heterogeneous biology to treatment options.
    Wilson NR; Acikgoz Y; Hasanov E
    Int J Cancer; 2024 Mar; 154(6):947-961. PubMed ID: 37823185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials.
    de Velasco G; McKay RR; Lin X; Moreira RB; Simantov R; Choueiri TK
    Clin Genitourin Cancer; 2017 Dec; 15(6):652-660.e1. PubMed ID: 28410911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes of nivolumab plus ipilimumab in patients with metastatic non-clear cell renal cell carcinoma: Real-world data from a Japanese multicenter retrospective study.
    Izumi K; Inoue M; Washino S; Shirotake S; Kagawa M; Takeshita H; Miura Y; Hyodo Y; Oyama M; Kawakami S; Miyagawa T; Saito K; Kageyama Y
    Int J Urol; 2023 Sep; 30(9):714-721. PubMed ID: 36541136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review.
    Bersanelli M; Brunelli M; Gnetti L; Maestroni U; Buti S
    Ther Adv Med Oncol; 2020; 12():1758835920915303. PubMed ID: 32550862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma.
    Hutson TE; Michaelson MD; Kuzel TM; Agarwal N; Molina AM; Hsieh JJ; Vaishampayan UN; Xie R; Bapat U; Ye W; Jain RK; Fishman MN
    Eur Urol; 2021 Aug; 80(2):162-170. PubMed ID: 33867192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Pazopanib in Non-Clear Cell Renal Cell Carcinoma: A Systematic Review.
    Sneed GT; Lee S; Brown JN; Hammond JM
    Clin Genitourin Cancer; 2019 Dec; 17(6):419-424. PubMed ID: 31585694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pazopanib for the Treatment of Non-clear Cell Renal Cell Carcinoma: A Single-Arm, Open-Label, Multicenter, Phase II Study.
    Jung KS; Lee SJ; Park SH; Lee JL; Lee SH; Lim JY; Kang JH; Lee S; Rha SY; Lee KH; Kim HY; Lim HY
    Cancer Res Treat; 2018 Apr; 50(2):488-494. PubMed ID: 28546525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal management of metastatic renal cell carcinoma: current status.
    Escudier B; Albiges L; Sonpavde G
    Drugs; 2013 Apr; 73(5):427-38. PubMed ID: 23572408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.
    Coppin C; Kollmannsberger C; Le L; Porzsolt F; Wilt TJ
    BJU Int; 2011 Nov; 108(10):1556-63. PubMed ID: 21952069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-clear cell renal cell carcinoma: does the mammalian target of rapamycin represent a rational therapeutic target?
    Albiges L; Molinie V; Escudier B
    Oncologist; 2012; 17(8):1051-62. PubMed ID: 22807514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-Clear Cell Renal Cell Carcinoma - Pathology and Treatment Options.
    Ahrens M; Scheich S; Hartmann A; Bergmann L;
    Oncol Res Treat; 2019; 42(3):128-135. PubMed ID: 30799404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial.
    Barata PC; Chehrazi-Raffle A; Allman KD; Asnis-Alibozek A; Kasturi V; Pal SK
    Oncologist; 2023 Oct; 28(10):894-900. PubMed ID: 37315114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.